The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
ApexOnco Front Page
Recent articles
What could be the four HengRui assets picked up by Bristol?
On a cross-trial basis varegacestat beats Ogsiveo.
No fewer than four ADCs with this target start human testing.
The group will start a pivotal trial of samuraciclib following promising second-line results.
The company is set to start a phase 2/3 trial this month.
Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
